{"pub": "investing.com", "url": "https://ca.investing.com/news/stock-market-news/briefxortx-therapeutics-announces-positive-phase-2-results-in-type-2-diabetic-nephropathy-1972041", "downloaded_at": "2019-09-20 02:29:08.557818+00:00", "title": "BRIEF-XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy", "language": "en", "text": "BRIEF-XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy\n\nStock Markets 1 hour ago (Sep 19, 2019 21:20)\n\n\u00a9 Reuters. BRIEF-XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy Sept 19 (Reuters) - XORTX Therapeutics Inc : * XORTX ANNOUNCES POSITIVE PHASE 2 RESULTS IN TYPE 2 DIABETIC NEPHROPATHY (T2DN) * XORTX THERAPEUTICS INC - STUDY ACHIEVED PRIMARY ENDPOINT FOR EFFICACY OF THIS STUDY AND TMX-049 WAS WELL TOLERATED\n\nBRIEF-XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy", "description": "BRIEF-XORTX Therapeutics Announces Positive Phase 2 Results In Type 2 Diabetic Nephropathy", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXMPEB0508S_L.jpg", "published_at": "2019-09-20"}